Cargando…

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer’s disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3–7 of the Aβ peptide. Aducanumab discriminates between monomer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arndt, Joseph W., Qian, Fang, Smith, Benjamin A., Quan, Chao, Kilambi, Krishna Praneeth, Bush, Martin W., Walz, Thomas, Pepinsky, R. Blake, Bussière, Thierry, Hamann, Stefan, Cameron, Thomas O., Weinreb, Paul H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913127/ https://www.ncbi.nlm.nih.gov/pubmed/29686315 http://dx.doi.org/10.1038/s41598-018-24501-0

Ejemplares similares

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Structure-based cross-docking analysis of antibody–antigen interactions
por: Kilambi, Krishna Praneeth, et al.
Publicado: (2017)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Protein-Protein Docking with Dynamic Residue Protonation States
por: Kilambi, Krishna Praneeth, et al.
Publicado: (2014)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
por: Salloway, Stephen, et al.
Publicado: (2021)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

Targeted DNA Methylation Using an Artificially Bisected M.HhaI Fused to Zinc Fingers
por: Chaikind, Brian, et al.
Publicado: (2012)

Correction: Targeted DNA Methylation Using an Artificially Bisected M.HhaI Fused to Zinc Fingers
por: Chaikind, Brian, et al.
Publicado: (2014)

Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation
por: Hane, Francis, et al.
Publicado: (2014)

Stable, Metastable, and Kinetically Trapped Amyloid Aggregate Phases
por: Miti, Tatiana, et al.
Publicado: (2014)

Influence of denaturants on amyloid β42 aggregation kinetics
por: Weiffert, Tanja, et al.
Publicado: (2022)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation
por: Garai, Kanchan, et al.
Publicado: (2014)

Kinetic Control of Parallel versus Antiparallel Amyloid Aggregation via Shape of the Growing Aggregate
por: Zanjani, Ali Asghar Hakami, et al.
Publicado: (2019)

Modeling of chemical inhibition from amyloid protein aggregation kinetics
por: Vázquez, José Antonio
Publicado: (2014)

Kinetics of Amyloid Aggregation: A Study of the GNNQQNY Prion Sequence
por: Nasica-Labouze, Jessica, et al.
Publicado: (2012)

A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease
por: Leinenga, Gerhard, et al.
Publicado: (2021)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6sf5av8l095noohhnsopd7bhnn